Evidence map›Paper›PMID 32418172›Full record

ArticlePituitary2020

Metabolic syndrome and its components in adult hypopituitary patients.

Simone Yae Abe, Kamila Souza Dos Santos, Bruna Fernanda Battistuzzi Barbosa, Claudia Maria Perera Biondo, Débora Takito, Sayuri Kuhnen Hayashi, Victor Galvani Vianna Amarilla, Anderson Zampier Ulbrich, Cesar Luiz Boguszewski

Abstract read
PubMed Publisher
In one paragraph

Article in Pituitary, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Simone Yae AbeCenter for Health Science, Medical School, Federal University of Parana, Curitiba, Brazil.
Kamila Souza Dos SantosCenter for Health Science, Medical School, Federal University of Parana, Curitiba, Brazil.
Bruna Fernanda Battistuzzi BarbosaCenter for Health Science, Medical School, Federal University of Parana, Curitiba, Brazil.
Claudia Maria Perera BiondoCenter for Health Science, Medical School, Federal University of Parana, Curitiba, Brazil.
Débora TakitoCenter for Health Science, Medical School, Federal University of Parana, Curitiba, Brazil.
Sayuri Kuhnen HayashiCenter for Health Science, Medical School, Federal University of Parana, Curitiba, Brazil.
Victor Galvani Vianna AmarillaCenter for Health Science, Medical School, Federal University of Parana, Curitiba, Brazil.
Anderson Zampier UlbrichResearch Group of Exercise Medicine, Department of Integrative Medicine, Federal University of Parana, Curitiba, Brazil.
Cesar Luiz BoguszewskiSEMPR (Endocrine Division), Department of Internal Medicine, Federal University of Parana, Curitiba, Brazil. clbogus@uol.com.br.ORCID http://orcid.org/0000-0001-7285-7941
Universidade Federal do Paraná · BRHospital de Clínicas Universidade Federal do Paraná · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo evaluate the prevalence of metabolic syndrome (MetS) and its components in adult hypopituitary patients. PATIENTS AND

methodsRetrospective, cross-sectional analysis of a cohort of hypopituitary adult patients followed in a single reference center for pituitary diseases. MetS was defined by the National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATP III) criteria. Patients with 18 years or older, presenting two or more anterior pituitary deficiencies associated or not with diabetes insipidus (DI), were included, while patients with hypopituitarism due to Acromegaly or Cushing's disease were excluded.

resultsWe studied 99 hypopituitary patients (52 males, mean age 50.1 ± 16.3 years, mean age at diagnosis 33.7 ± 17.6 years) who have been followed for a mean time of 15.9 ± 10.1 years. Hypothalamic-pituitary tumors and non-tumoral etiologies were observed in 53.4% and 46.6% of the cases, respectively. FSH/LH, GH, TSH, ACTH deficiency and DI was present in 99%, 98.6%, 96%, 81.8%, and 23.2%, respectively. The prevalence of MetS was 39.4% and was significantly higher in patients older than 50 years (p = 0.02), overweight/obese (p < 0.001), with hypopituitarism diagnosed in adult life (p = 0.02), who did not replace GH (p = 0.004) and in smokers (p = 0.007). In the logistic regression model, body mass index (BMI) and GH replacement were significantly associated with the presence of MetS. Reduced HDL cholesterol was the most prevalent component of MetS in hypopituitary patients.

conclusionsMetS is a common finding in adult hypopituitary patients, which is mainly influenced by increased BMI and untreated GH deficiency. Trial Registration number (Plataforma Brasil): CAAE 51008815.2.0000.0096 (May 31, 2017) .

Indexed as

Adrenocorticotropic HormoneAdultAgedAged, 80 and overBrazilCholesterol, HDLCross-Sectional StudiesDiabetes InsipidusDyslipidemiasFemaleHuman Growth HormoneHumansHypogonadismHypopituitarismMaleMetabolic SyndromeAdrenocorticotropic HormoneCholesterol, HDLHuman Growth HormoneGrowth hormone deficiencyHormone replacement therapyHypopituitarismMetabolic syndrome

Identifiers

PMID32418172
OpenAlexW3024759617

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.